New copycat drug for psoriasis tested in healthy volunteers
NCT ID NCT07200986
Summary
This early-stage study aims to see if a new, potentially cheaper version of the drug Taltz (called CT-P52) behaves the same way in the body as the original. It involves 218 healthy adults who will receive a single dose of either drug. Researchers will measure drug levels in the blood and check for side effects to see if the two versions are similar.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEALTHY PARTICIPANTS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
CHA Bundang Medical Center
Seongnam-si, Gyeonggi-do, South Korea
-
Chungbuk National University Hospital
Cheongju-si, North Chungcheong, South Korea
-
Inje University Busan Paik Hospital
Busan, Busanjin-gu, South Korea
-
Seoul National University Bundang Hospital
Seongnam-si, Gyeonggi-do, South Korea
-
Seoul National University Hospital
Seoul, South Korea
Conditions
Explore the condition pages connected to this study.